Table 3.

Conditions shown to respond to omalizumab/anti-IgE* therapy

Condition	Reference
Allergic rhinitis	[66,69,85-89]
Allergic asthma:
• Moderate-severe persistent disease	[55,64,90-94]
• Steroid-sparing effect	[57,95,96]
Churg-Strauss syndrome	[97,98]
Peanut anaphylaxis*	[52,70,71,99,100]
Uticaria	[78]
Angioedema	[101]
Immunotherapy reactions	[102]
Rubber latex allergy	[79]